After completing this activity participants will be able to:
- Describe the stages of office-based buprenorphine treatment, basic regulations, and requirements
- Relate buprenorphine’s pharmacological properties to its drug effects
- Understand the physiological effects of opioids and opioid treatments on patients
- Identify, assess, and diagnose opioid use disorder in patients
- Use medical and substance use disorder history information to assess patients in terms of suitability for treatment with buprenorphine
- Describe effective and successful treatment of patients in buprenorphine treatment and complications that may arise
- Describe how buprenorphine treatment guidelines are adapted to needs of specific patient populations, including those with psychiatric comorbidities, adolescents, the elderly, pregnant women, methadone transfers, and patients with pain
- Prescribe, refer, or implement appropriate psychosocial therapies for treating opioid use disorder for patients
- Monitor patients being treated with opioids for chronic pain to screen for substance use problems
- Identify patients with a high risk of opioid use disorder or other misuse before prescribing any opioids
- Identify risk for diversion and overdose by patients being treated with opioids and take prevention steps
- Use a patient-centered, non-authoritarian, collaborative approach to work with a patient to change substance use behaviors or other health behaviors
Modules in this Training Activity
Audience and Accreditation
Audience: Medical Residents, Medical Students
|AMA PRA Category 1 Credit(s)™||12 hr(s)||7/1/19||6/30/22|
Accreditation Statement: Clinical Tools, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credit™ Designation Statement: Clinical Tools, Inc. designates this enduring material for a maximum of 12 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A letter of completion for 12 hours is available.
A score of 70% on the post-test is required to complete the activity.
Development of this website was funded by grant #R44DA12066, contract #HHSN271200655304C, contracts #HHSN271200900003C and Grant #1R44DA027245-01 from the National Institute on Drug Abuse (NIDA), as well as grants #1R43AA020456-01A1 and #2R44AA020456-02 from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health.